Stock Analysis

Indo Borax & Chemicals Third Quarter 2025 Earnings: EPS: ₹2.83 (vs ₹2.56 in 3Q 2024)

NSEI:INDOBORAX
Source: Shutterstock

Indo Borax & Chemicals (NSE:INDOBORAX) Third Quarter 2025 Results

Key Financial Results

  • Revenue: ₹375.1m (down 15% from 3Q 2024).
  • Net income: ₹90.7m (up 10% from 3Q 2024).
  • Profit margin: 24% (up from 19% in 3Q 2024). The increase in margin was driven by lower expenses.
  • EPS: ₹2.83 (up from ₹2.56 in 3Q 2024).
earnings-and-revenue-history
NSEI:INDOBORAX Earnings and Revenue History February 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Indo Borax & Chemicals shares are down 10% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Indo Borax & Chemicals you should know about.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:INDOBORAX

Indo Borax & Chemicals

Manufactures and sells boron and lithium products in India.

Adequate balance sheet average dividend payer.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor